Phase 2
Completed N=10
Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma
Source: ClinicalTrials.gov NCT03262389 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Mar 2021
Primary outcomePrimary: Mean Multiple Myeloma Lesions Detected — 4.6; 4.4; 1.1; 1.0 number of lesions
Summary
Investigators are doing this study to determine which of four imaging techniques: Fludeoxyglucose Positron Emission Tomography (18 FDG PET) computerized tomography (CT), 18 FDG PET Magnetic resonance imaging (MRI), C-11 acetate PET CT, and C-11 acetate PET MRI) is the best test for finding sites of active myeloma disease.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Multiple Myeloma Lesions Detected |
4.6; 4.4; 1.1; 1.0 | — |
| SECONDARY Visual Image Analysis of Detected Multiple Myeloma Lesions |
3.1; 3.3; 1.9; 2.0 | — |
Eligibility Criteria
Inclusion Criteria
- Patients being staged for multiple myeloma as follows: new diagnosis, high risk smoldering multiple myeloma, relapsed as defined by investigator
- Patients who have undergone standard of care workup
- 300 pounds or less
- Can provide informed consent
- Scheduled for a clinically indicated F-18 FDG PET scan
- English speaking
Exclusion Criteria
- Pregnant, breast feeding
- Concurrent active non-multiple myeloma malignancy
- Contraindication to PET MRI
- Previous Type I or Type II Diabetes mellitus or a fasting blood glucose >150 mg/dl
Data sourced from ClinicalTrials.gov (NCT03262389). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.